Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis

BACKGROUND: Previous studies demonstrated substantial economic and comorbidity burden associated with psoriasis (PsO) before biologics were available. Biologics have changed PsO treatment paradigms and potentially improved patient outcomes. There is a need to reassess the economic and comorbidity bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Feldman, Steven R., Zhao, Yang, Shi, Lizheng, Tran, Mary Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397856/
https://www.ncbi.nlm.nih.gov/pubmed/26402388
http://dx.doi.org/10.18553/jmcp.2015.21.10.874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397856/
https://www.ncbi.nlm.nih.gov/pubmed/26402388
http://dx.doi.org/10.18553/jmcp.2015.21.10.874

Ejemplares similares